Background: Antibody-dependent cellular cytotoxicity (ADCC) has been linked with protection against HIV-1. In the RV144 trial that showed an estimated efficacy of 31%, high levels of ADCC inversely correlate with infection risk. Non-neutralizing epitopes in the C1 region of gp120 have been implicated as potential targets for protective antibody responses elicited by vaccination, although antibody-binding titers against these epitopes do not correlate with protection. We hypothesized that differences in the mode of epitope recognition may be responsible for large differences in ADCC activities between antibodies targeting the C1 region of gp120. Methodology: For atomic level definition of binding epitopes, we determined the structures of two monoclonal antibodies (mAbs), N5-i5 and 2.2c, that target the C1 region of gp120, in complex with gp120 core in the CD4-trigerred conformation. ADCC measurements were carried out using CEM-NKr- CCR5 target cells sensitized with recombinant gp120 from the HIV-1Ba-L isolate. Fluorescently labeled N5-i5 was used in a competition strategy to measure N5-i5 and 2.2c binding to CEM-NKr-CCR5 target cells sensitized with gp120. Results: Monoclonal antibodies (mAb) N5-i5 and 2.2c differed 75-fold in their ADCC potency. N5-i5 and 2.2c recognized overlapping but distinct epitopes in the C1-C2 region of gp120. While N5-i5 contacted topological layers 1 and 2 of gp120, 2.2c contacts were restricted predominantly to layer 1 with few contacts with layer 2. We also found that the heavy and light chains of bound N5-i5 and 2.2c were switched. Hybrid variants of the antibodies with their VH and VL domains swapped, showed no difference in cell surface binding. While the ADCC potency for N5-i5 did not show any significant difference between the wild-type and the VH/VL swapped version, swapping VH and VL domains improved ADCC potency of 2.2c by 7-fold. Conclusions: The ability of antibody to cross-link antigen and positioning of its CH2 domain were found to contribute to ADCC potency, indicating that ADCC function depends on the orientation of antibody binding even when overlapping epitopes are involved. These data provide a framework for understanding the discordance between epitope-specific binding assays and ADCC as correlates of reduced infection risk in the RV144 trial. Further, they set the stage for an atomic level understanding of the role of precise epitope targeting in ADCC and similar Fc-mediated effector functions of antibodies.